GTR Test Accession:
Help
GTR000520392.6
CAP
Last updated in GTR:
2021-01-19
View version history
GTR000520392.6,
last updated:
2021-01-19
GTR000520392.5,
last updated:
2020-08-17
GTR000520392.4,
last updated:
2019-08-13
GTR000520392.3,
last updated:
2018-08-20
GTR000520392.2,
last updated:
2016-10-17
GTR000520392.1,
registered in GTR:
2014-12-05
Last annual review date for the lab: 2024-07-22
LinkOut
At a Glance
Test purpose:
Help
Diagnosis;
Monitoring;
Mutation Confirmation; ...
Conditions (27):
Help
Li-Fraumeni syndrome 2;
Aplastic anemia;
Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency
more...
Genes (66):
Help
Methods (2):
Help
Molecular Genetics - Deletion/duplication analysis: Next-Generation (NGS)/Massively parallel sequencing (MPS); ...
Target population: Help
Not provided
Clinical validity:
Help
Not provided
Clinical utility:
Help
Establish or confirm diagnosis
Ordering Information
Offered by:
Help
Specimen Source:
Help
- Fibroblasts
- View specimen requirements
Who can order: Help
- Genetic Counselor
- Health Care Provider
- Licensed Physician
- Nurse Practitioner
- Physician Assistant
- Registered Nurse
CPT codes:
Help
Contact Policy:
Help
Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.
How to Order:
Help
•All samples should be shipped via overnight delivery at room temperature.
•No weekend or holiday deliveries.
•Label each specimen with the patient’s name, date of birth and date sample collected.
•Send specimens with complete requisition and consent form, otherwise, specimen processing may be delayed.
Order URL
•No weekend or holiday deliveries.
•Label each specimen with the patient’s name, date of birth and date sample collected.
•Send specimens with complete requisition and consent form, otherwise, specimen processing may be delayed.
Order URL
Test service:
Help
Clinical Testing/Confirmation of Mutations Identified Previously
Confirmation of research findings
Confirmation of research findings
Test additional service:
Help
Custom Prenatal Testing
Custom mutation-specific/Carrier testing
Custom mutation-specific/Carrier testing
Test development:
Help
Test developed by laboratory (no manufacturer test name)
Informed consent required:
Help
No
Pre-test genetic counseling required:
Help
Decline to answer
Post-test genetic counseling required:
Help
Decline to answer
Recommended fields not provided:
Test Order Code,
Lab contact for this test,
Test strategy
Conditions
Help
Total conditions: 27
| Condition/Phenotype | Identifier |
|---|
Test Targets
Genes
Help
Total genes: 66
| Gene | Associated Condition | Germline or Somatic | Allele (Lab-provided) | Variant in NCBI |
|---|
Methodology
Total methods: 2
Method Category
Help
Test method
Help
Instrument *
Deletion/duplication analysis
Next-Generation (NGS)/Massively parallel sequencing (MPS)
Sequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
* Instrument: Not provided
Clinical Information
Test purpose:
Help
Diagnosis;
Monitoring;
Mutation Confirmation;
Pre-symptomatic;
Prognostic;
Risk Assessment
Clinical utility:
Help
Establish or confirm diagnosis
View citations (1)
- Use of the latent image technique to develop and evaluate problem-solving skills. Schwabbauer ML, et al. Am J Med Technol. 1975;41(12):457-62. doi:10.7326/0003-4819-83-6-834. PMID: 1. Churpek, J.E. and K. Onel, Heritability of hematologic malignancies: from pedigrees to genomics. Hematol Oncol Clin North Am, 2010. 24(5): p. 939-72. 2. Goldin, L.R., et al., Familial aggregation of Hodgkin lymphoma and related tumors. Cancer, 2004. 100(9): p. 1902-8. 3. Kerzin-Storrar, L., et al., Incidence of familial Hodgkin's disease. Br J Cancer, 1983. 47(5): p. 707-12. 4. Segel, G.B. and M.A. Lichtman, Familial (inherited) leukemia, lymphoma, and myeloma: an overview. Blood Cells Mol Dis, 2004. 32(1): p. 246-61. 5. Mueller, B.U. and P.A. Pizzo, Cancer in children with primary or secondary immunodeficiencies. J Pediatr, 1995. 126(1): p. 1-10. 6. Straus, S.E., et al., The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood, 2001. 98(1): p. 194-200. 7. Coffey, A.J., et al., Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH.
Variant Interpretation:
What is the protocol for interpreting a variation as a VUS?
Help
Variants are identified and evaluated using a custom collection of bioinformatic tools and comprehensively interpreted by our team of directors and genetic counselors.
Variants are identified and evaluated using a custom collection of bioinformatic tools and comprehensively interpreted by our team of directors and genetic counselors.
Are family members with defined clinical status recruited to assess significance of VUS without charge?
Help
Yes.
Yes.
Will the lab re-contact the ordering physician if variant interpretation changes?
Help
Yes. Yes
Yes. Yes
Recommended fields not provided:
Clinical validity,
Target population,
Is research allowed on the sample after clinical testing is complete?,
Sample negative report,
Sample positive report
Technical Information
Test Procedure:
Help
Positive test results are confirmed using repeat sequence analysis.
Test Confirmation:
Help
Positive test results are confirmed using repeat sequence analysis.
Availability:
Help
Tests performed
Entire test performed in-house
Entire test performed in-house
Analytical Validity:
Help
Analytical Sensitivity 99-100% Accuracy 100% Precision 100%
Assay limitations:
Help
This assay covers the coding and immediate flanking regions of the included genes. Variants in the promoter region and in other non-coding regions will not be detected. Variants that occur within regions of high homology and/or repetitiveness may not be detected due to issues with alignment. The technical sensitivity of …
View more
Proficiency testing (PT):
Is proficiency testing performed for this test?
Help
Yes
Method used for proficiency testing: Help
Formal PT program
PT Provider: Help
American College of Medical Genetics / College of American Pathologists, ACMG/CAP
Yes
Method used for proficiency testing: Help
Formal PT program
PT Provider: Help
American College of Medical Genetics / College of American Pathologists, ACMG/CAP
VUS:
Software used to interpret novel variations
Help
A custom collection of bioinformatics tools.
Laboratory's policy on reporting novel variations Help
All novel and/or potentially pathogenic variants are confirmed by Sanger sequencing
A custom collection of bioinformatics tools.
Laboratory's policy on reporting novel variations Help
All novel and/or potentially pathogenic variants are confirmed by Sanger sequencing
Recommended fields not provided:
Citations to support assay limitations,
Description of internal test validation method,
Citations for Analytical validity,
Description of PT method,
Major CAP category, CAP category, CAP test list
Regulatory Approval
FDA Review:
Help
Category:
FDA exercises enforcement discretion
Additional Information
Reviews:
Suggested reading:
Clinical resources:
Molecular resources:
Consumer resources:
IMPORTANT NOTE:
NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading.
NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice.
Patients and consumers
with specific questions about a genetic test should contact a health care provider or a genetics professional.